Addiction severity index

ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

Retrieved on: 
Tuesday, October 24, 2023
Standard of care, AD, George Washington University School of Medicine & Health Sciences, Clinical trial, Outline of health sciences, Internet, Physician, Congress, MD, Research, Contract research organization, Dupilumab, Drug development, Addiction severity index, European Academy of Allergy and Clinical Immunology, Disease, Webcast, ASLN, EASI, UCLA, Atopic dermatitis, Patient, Pharmaceutical industry, Dermatology, Venereology

During the event, ASLAN will present additional analyses of the TREK-AD patient population building on data recently published at the 32nd European Academy of Dermatology and Venereology (EADV) Congress.

Key Points: 
  • During the event, ASLAN will present additional analyses of the TREK-AD patient population building on data recently published at the 32nd European Academy of Dermatology and Venereology (EADV) Congress.
  • ASLAN will also present new insights on the AD treatment landscape based on a recently conducted survey of physicians and AD patients in the US.
  • “We are pleased to be contributing to today’s discussion that aims to spark a dialogue on the changing AD patient profile that presents in clinical studies.
  • Register here to attend the webcast or watch the replay of the event, which will be available for 180 days.

Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years

Retrieved on: 
Friday, October 20, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Almirall, Lilly, Eli Lilly and Company, AD, Aes, Eli Lilly, Adherence, Conference, Maintenance, Addiction severity index, Conditional sentence, IGA, Shingles, Abstract, The New England Journal of Medicine, Conjunctivitis, British Journal of Dermatology, Atopic dermatitis, Patient, Pharmaceutical industry, Dermatology, Tree-adjoining grammar, EASI

In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.

Key Points: 
  • In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.
  • The most common side effects of lebrikizumab were conjunctivitis, injection site reactions and shingles (herpes zoster).
  • “Results from ADjoin reinforce the strong efficacy and safety profile of lebrikizumab seen in the other Phase 3 atopic dermatitis trials.
  • Lilly has exclusive rights for development and commercialization of lebrikizumab in the U.S. and the rest of the world outside Europe.

Dermavant Announces New Positive Pruritus Data for VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as Two Years Old with Atopic Dermatitis at the EADV Congress 2023

Retrieved on: 
Thursday, October 12, 2023
Medical Supplies, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Congress, Journal of the European Academy of Dermatology and Venereology, Validation, Therapy, Caregiver, Atopic dermatitis, JD, Ageing, Addiction severity index, Itch, Patient, QD, EASI, Body surface area, Pharmaceutical industry, Dermatology, MD, Venereology

The new data presented at EADV 2023 contains daily recorded PP-NRS scores of patients in ADORING 1 and ADORING 2 on VTAMA cream for the first time.

Key Points: 
  • The new data presented at EADV 2023 contains daily recorded PP-NRS scores of patients in ADORING 1 and ADORING 2 on VTAMA cream for the first time.
  • Patients aged ≥12 years old self-completed the PP-NRS, while caregivers completed it for children aged
  • Improvements in daily PP-NRS scores with tapinarof versus vehicle continued through the first 2 weeks and through Week 8 of both trials.
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.